135 related articles for article (PubMed ID: 16912915)
1. Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines.
Journé F; Magné N; Chaboteaux C; Kinnaert E; Bauss F; Body JJ
Clin Exp Metastasis; 2006; 23(2):135-47. PubMed ID: 16912915
[TBL] [Abstract][Full Text] [Related]
2. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
3. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
Journe F; Chaboteaux C; Magne N; Duvillier H; Laurent G; Body JJ
Breast Cancer Res; 2006; 8(1):R2. PubMed ID: 16417650
[TBL] [Abstract][Full Text] [Related]
4. Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.
Journé F; Kheddoumi N; Chaboteaux C; Duvillier H; Laurent G; Body JJ
Breast Cancer Res; 2008; 10(1):R4. PubMed ID: 18190680
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
[TBL] [Abstract][Full Text] [Related]
6. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
Michigami T; Hiraga T; Williams PJ; Niewolna M; Nishimura R; Mundy GR; Yoneda T
Breast Cancer Res Treat; 2002 Oct; 75(3):249-58. PubMed ID: 12353814
[TBL] [Abstract][Full Text] [Related]
7. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
Magnetto S; Boissier S; Delmas PD; Clezardin P
Int J Cancer; 1999 Oct; 83(2):263-9. PubMed ID: 10471537
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines.
Epplen R; Stöckle M; Engelmann U; Heidenreich A; Ohlmann CH
Acta Oncol; 2011 Jan; 50(1):127-33. PubMed ID: 20429730
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
10. Ibandronate: its role in metastatic breast cancer.
Cameron D; Fallon M; Diel I
Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
[TBL] [Abstract][Full Text] [Related]
11. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.
Ibrahim T; Liverani C; Mercatali L; Sacanna E; Zanoni M; Fabbri F; Zoli W; Amadori D
Int J Oncol; 2013 Apr; 42(4):1263-70. PubMed ID: 23403907
[TBL] [Abstract][Full Text] [Related]
14. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Ebert R; Meissner-Weigl J; Zeck S; Määttä J; Auriola S; Coimbra de Sousa S; Mentrup B; Graser S; Rachner TD; Hofbauer LC; Jakob F
Mol Cancer; 2014 Dec; 13():265. PubMed ID: 25496233
[TBL] [Abstract][Full Text] [Related]
15. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection.
Pecherstorfer M; Ludwig H; Schlosser K; Buck S; Huss HJ; Body JJ
J Bone Miner Res; 1996 May; 11(5):587-93. PubMed ID: 9157773
[TBL] [Abstract][Full Text] [Related]
16. In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells.
Ural AU; Avcu F; Candir M; Guden M; Ozcan MA
Breast Cancer Res; 2006; 8(4):R52. PubMed ID: 16925824
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib effects on the radiation response of endothelial and breast tumor cells.
El Kaffas A; Al-Mahrouki A; Tran WT; Giles A; Czarnota GJ
Microvasc Res; 2014 Mar; 92():1-9. PubMed ID: 24215790
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion.
Syrigos KN; Michalaki V; Mitromaras A; Pliarchopoulou F; Katirtzoglou N; Antonaki E; Roussou P
In Vivo; 2002; 16(5):361-3. PubMed ID: 12494878
[TBL] [Abstract][Full Text] [Related]
19. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.
Heras P; Karagiannis S; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2007 Nov; 16(6):539-42. PubMed ID: 17944770
[TBL] [Abstract][Full Text] [Related]
20. Influence of clodronate on breast cancer cells in vitro.
Busch M; Rave-Fränk M; Hille A; Dühmke E
Eur J Med Res; 1998 Sep; 3(9):427-31. PubMed ID: 9737889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
